

The Bruton's Tyrosine Kinase Inhibitor Evobrutinib Demonstrates Superior Efficacy in Targeting Compartmentalized Neuroinflammation Compared to Anti-CD20 Treatment


Hania Kebir¹, Cen Li¹, Michael J. May², Molly E. Church¹, Ursula Boschert³, and Jorge I. Alvarez¹

¹Department of Pathobiology, and ²Department of Biomedical Sciences, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA.


³Ares Trading SA, Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany.




Challenges in modeling the pathology of MS progression



Progressive experimental autoimmune encephalomyelitis (pEAE) model



Targeting compartmentalized neuroinflammation with the (BTKi) Evobrutinib



Effect of anti-CD20 depleting antibodies on the pEAE model

